Musa FB - Search Results

1

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.

Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Eskander RN, et al. Among authors: musa fb. N Engl J Med. 2023 Jun 8;388(23):2159-2170. doi: 10.1056/NEJMoa2302312. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972022 Free PMC article. Clinical Trial.

2

A pharmacokinetic evaluation of topotecan as a cervical cancer therapy.

Musa F, Blank S, Muggia F. Musa F, et al. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):215-24. doi: 10.1517/17425255.2013.758249. Expert Opin Drug Metab Toxicol. 2013. PMID: 23320990 Review.

3

Ovarian pregnancy and a copper intrauterine device.

Brandt JS, Musa F, Wang X, Shaktman BD. Brandt JS, et al. Rev Obstet Gynecol. 2010 Summer;3(3):81. Rev Obstet Gynecol. 2010. PMID: 21364858 Free PMC article. No abstract available.

4

Neoadjuvant chemotherapy in patients with advanced endometrial cancer.

Khouri OR, Frey MK, Musa F, Muggia F, Lee J, Boyd L, Curtin JP, Pothuri B. Khouri OR, et al. Cancer Chemother Pharmacol. 2019 Aug;84(2):281-285. doi: 10.1007/s00280-019-03838-x. Epub 2019 Apr 12. Cancer Chemother Pharmacol. 2019. PMID: 30980132

5

Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report.

Blank SV, Huh WK, Bell M, Dilley S, Hardesty M, Hoskins ER, Lachance J, Musa F, Prendergast E, Rimel BJ, Shahin M, Valea F. Blank SV, et al. Gynecol Oncol. 2023 Apr;171:76-82. doi: 10.1016/j.ygyno.2023.02.008. Epub 2023 Feb 22. Gynecol Oncol. 2023. PMID: 36827841

6

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).

Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR. Chi DS, et al. Gynecol Oncol. 2012 Jan;124(1):10-4. doi: 10.1016/j.ygyno.2011.08.014. Epub 2011 Sep 13. Gynecol Oncol. 2012. PMID: 21917306

7

Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.

Musa F, Pothuri B, Blank SV, Ling HT, Speyer JL, Curtin J, Boyd L, Li X, Goldberg JD, Muggia F, Tiersten A. Musa F, et al. Gynecol Oncol. 2017 Feb;144(2):279-284. doi: 10.1016/j.ygyno.2016.11.043. Epub 2016 Dec 5. Gynecol Oncol. 2017. PMID: 27931751 Clinical Trial.

8

Preoperative experience for public hospital patients with gynecologic cancer: Do structural barriers widen the gap?

Frey MK, Moss HA, Musa F, Rolnitzky L, David-West G, Chern JY, Boyd LR, Curtin JP. Frey MK, et al. Cancer. 2016 Mar 15;122(6):859-67. doi: 10.1002/cncr.29859. Epub 2016 Jan 27. Cancer. 2016. PMID: 26938270 Free article.

9

Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer.

Musa FB, Brouwer E, Ting J, Schwartz NRM, Surinach A, Bloudek L, Ramsey SD. Musa FB, et al. Gynecol Oncol. 2022 Mar;164(3):645-650. doi: 10.1016/j.ygyno.2021.12.028. Epub 2022 Jan 12. Gynecol Oncol. 2022. PMID: 35031189

10

Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.

Musa F, Alard A, David-West G, Curtin JP, Blank SV, Schneider RJ. Musa F, et al. Mol Cancer Ther. 2016 Jul;15(7):1557-67. doi: 10.1158/1535-7163.MCT-15-0926. Epub 2016 May 16. Mol Cancer Ther. 2016. PMID: 27196780 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters